ID   ENPP2_MOUSE             Reviewed;         862 AA.
AC   Q9R1E6; A8UH85; A8UH93; B2ZP54; Q6PDE0; Q99LG9;
DT   19-SEP-2002, integrated into UniProtKB/Swiss-Prot.
DT   10-FEB-2009, sequence version 3.
DT   22-JUL-2015, entry version 135.
DE   RecName: Full=Ectonucleotide pyrophosphatase/phosphodiesterase family member 2;
DE            Short=E-NPP 2;
DE            EC=3.1.4.39;
DE   AltName: Full=Autotaxin;
DE   AltName: Full=Extracellular lysophospholipase D;
DE            Short=LysoPLD;
DE   Flags: Precursor;
GN   Name=Enpp2; Synonyms=Npps2, Pdnp2;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   STRAIN=C57BL/6;
RX   PubMed=10702660;
RA   Piao J.-H., Matsuda Y., Nakamura H., Sano K.;
RT   "Assignment of Pdnp2, the gene encoding phosphodiesterase I/nucleotide
RT   pyrophosphatase 2, to mouse chromosome 15D2.";
RL   Cytogenet. Cell Genet. 87:172-174(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3), ENZYME REGULATION,
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND TISSUE SPECIFICITY.
RC   TISSUE=Adipocyte, and Skeletal muscle;
RX   PubMed=18175805; DOI=10.1074/jbc.M708705200;
RA   Giganti A., Rodriguez M., Fould B., Moulharat N., Coge F.,
RA   Chomarat P., Galizzi J.-P., Valet P., Saulnier-Blache J.-S.,
RA   Boutin J.A., Ferry G.;
RT   "Murine and human autotaxin alpha, beta, and gamma isoforms: gene
RT   organization, tissue distribution, and biochemical characterization.";
RL   J. Biol. Chem. 283:7776-7789(2008).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=MRL/MpJ;
RA   Burgess-Herbert S.L., Shockley K., Sheehan S., Bickerstaff L.,
RA   Harwood B.I.V., Shen Y., Li R., Churchill G.A., Paigen B.;
RT   "Comparative genomics, experimental biology, and bioinformatics merge
RT   to narrow a QTL for HDL cholesterol on mouse chromosome 15 and human
RT   chromosome 8.";
RL   Submitted (APR-2008) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   STRAIN=C57BL/6J; TISSUE=Skin;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Adams M.D., Myers E.W., Smith H.O., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   STRAIN=C57BL/6, and FVB/N; TISSUE=Mammary gland, and Retina;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   INDUCTION, AND POSSIBLE FUNCTION IN OBESITY.
RX   PubMed=15700135; DOI=10.1007/s00125-004-1660-8;
RA   Boucher J., Quilliot D., Pradere J.P., Simon M.F., Gres S., Guigne C.,
RA   Prevot D., Ferry G., Boutin J.A., Carpene C., Valet P.,
RA   Saulnier-Blache J.S.;
RT   "Potential involvement of adipocyte insulin resistance in obesity-
RT   associated up-regulation of adipocyte lysophospholipase D/autotaxin
RT   expression.";
RL   Diabetologia 48:569-577(2005).
RN   [8]
RP   PROTEOLYTIC CLEAVAGE, SUBCELLULAR LOCATION, FUNCTION, GLYCOSYLATION,
RP   AND MUTAGENESIS OF 12-VAL--VAL-22; 12-VAL--GLY-27; 23-ASN--GLY-27;
RP   CYS-25; GLY-27; 27-GLY--ALA-30; 27-GLY--ARG-35; 30-ALA--ILE-33;
RP   30-ALA--GLY-41; 32-ARG--ARG-35; 36-ALA--GLU-40; ASN-53 AND ASN-410.
RX   PubMed=17208043; DOI=10.1016/j.bbalip.2006.11.010;
RA   Pradere J.P., Tarnus E., Gres S., Valet P., Saulnier-Blache J.S.;
RT   "Secretion and lysophospholipase D activity of autotaxin by adipocytes
RT   are controlled by N-glycosylation and signal peptidase.";
RL   Biochim. Biophys. Acta 1771:93-102(2007).
RN   [9]
RP   INTERDOMAIN DISULFIDE BOND, AND MUTAGENESIS OF 851-LEU--THR-853;
RP   LEU-851; LYS-852 AND THR-853.
RX   PubMed=19329427; DOI=10.1074/jbc.M900790200;
RA   Jansen S., Andries M., Derua R., Waelkens E., Bollen M.;
RT   "Domain interplay mediated by an essential disulfide linkage is
RT   critical for the activity and secretion of the metastasis-promoting
RT   enzyme autotaxin.";
RL   J. Biol. Chem. 284:14296-14302(2009).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 36-862 IN COMPLEXES WITH
RP   LYSOPHOSPHATIDIC ACID; ZINC AND CALCIUM IONS, FUNCTION, CATALYTIC
RP   ACTIVITY, COFACTOR, DISULFIDE BONDS, GLYCOSYLATION AT ASN-53; ASN-410
RP   AND ASN-524, SUBCELLULAR LOCATION, AND MUTAGENESIS OF PHE-210;
RP   LEU-213; ASN-230; LEU-243; GLU-247 AND PHE-249.
RX   PubMed=21240269; DOI=10.1038/nsmb.1998;
RA   Nishimasu H., Okudaira S., Hama K., Mihara E., Dohmae N., Inoue A.,
RA   Ishitani R., Takagi J., Aoki J., Nureki O.;
RT   "Crystal structure of autotaxin and insight into GPCR activation by
RT   lipid mediators.";
RL   Nat. Struct. Mol. Biol. 18:205-212(2011).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 51-58.
RX   PubMed=23027977; DOI=10.1073/pnas.1208017109;
RA   Kato K., Nishimasu H., Okudaira S., Mihara E., Ishitani R., Takagi J.,
RA   Aoki J., Nureki O.;
RT   "Crystal structure of Enpp1, an extracellular glycoprotein involved in
RT   bone mineralization and insulin signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:16876-16881(2012).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 36-862 IN COMPLEXES WITH
RP   INHIBITORS AND ZINC, GLYCOSYLATION AT ASN-53; ASN-410 AND ASN-524,
RP   CATALYTIC ACTIVITY, COFACTOR, AND DISULFIDE BOND.
RX   PubMed=23688339; DOI=10.1021/cb400150c;
RA   Kawaguchi M., Okabe T., Okudaira S., Nishimasu H., Ishitani R.,
RA   Kojima H., Nureki O., Aoki J., Nagano T.;
RT   "Screening and X-ray crystal structure-based optimization of autotaxin
RT   (ENPP2) inhibitors, using a newly developed fluorescence probe.";
RL   ACS Chem. Biol. 8:1713-1721(2013).
CC   -!- FUNCTION: Hydrolyzes lysophospholipids to produce lysophosphatidic
CC       acid (LPA) in extracellular fluids. Major substrate is
CC       lysophosphatidylcholine. Also can act on
CC       sphingosylphosphphorylcholine producing sphingosine-1-phosphate, a
CC       modulator of cell motility. Can hydrolyze, in vitro, bis-pNPP, to
CC       some extent pNP-TMP, and barely ATP. Involved in several motility-
CC       related processes such as angiogenesis and neurite outgrowth. Acts
CC       as an angiogenic factor by stimulating migration of smooth muscle
CC       cells and microtubule formation. Stimulates migration of melanoma
CC       cells, probably via a pertussis toxin-sensitive G protein. May
CC       have a role in induction of parturition. Possible involvement in
CC       cell proliferation and adipose tissue development. Tumor cell
CC       motility-stimulating factor. {ECO:0000269|PubMed:17208043,
CC       ECO:0000269|PubMed:21240269}.
CC   -!- CATALYTIC ACTIVITY: 1-alkyl-sn-glycero-3-phosphoethanolamine +
CC       H(2)O = 1-alkyl-sn-glycerol 3-phosphate + ethanolamine.
CC       {ECO:0000269|PubMed:21240269, ECO:0000269|PubMed:23688339}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC       Note=Binds 2 Zn(2+) ions per subunit.;
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC       Note=Binds 1 Ca(2+) ion per subunit.;
CC   -!- ENZYME REGULATION: Inhibited by lysophosphatidic acid (LPA) and
CC       sphingosine-1-phosphate (S1P) (By similarity). Inhibited by EDTA
CC       and EGTA. {ECO:0000250, ECO:0000269|PubMed:18175805}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=12.9 mM for pNppp (isoform 1) {ECO:0000269|PubMed:18175805};
CC         KM=4.4 mM for pNppp (isoform 2) {ECO:0000269|PubMed:18175805};
CC         KM=11.8 mM for pNppp (isoform 3) {ECO:0000269|PubMed:18175805};
CC         Vmax=1.9 nmol/min/ug enzyme with pNppp as substrate (isoform 1)
CC         {ECO:0000269|PubMed:18175805};
CC         Vmax=0.35 nmol/min/ug enzyme with pNppp as substrate (isoform 2)
CC         {ECO:0000269|PubMed:18175805};
CC         Vmax=1.8 nmol/min/ug enzyme with pNppp as substrate (isoform 3)
CC         {ECO:0000269|PubMed:18175805};
CC       pH dependence:
CC         Optimum pH is 8.0 for isoforms 1, 2 and 3.
CC         {ECO:0000269|PubMed:18175805};
CC       Temperature dependence:
CC         Isoforms 1 and 3 have maximum activity from 45 to 55 degrees
CC         Celsius. {ECO:0000269|PubMed:18175805};
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:17208043,
CC       ECO:0000269|PubMed:21240269}. Note=Secreted by most body fluids
CC       including serum and CSF. Also by adipocytes and numerous cancer
CC       cells (By similarity). {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=Beta;
CC         IsoId=Q9R1E6-1; Sequence=Displayed;
CC       Name=2; Synonyms=Alpha;
CC         IsoId=Q9R1E6-2; Sequence=VSP_036396;
CC       Name=3; Synonyms=Gamma;
CC         IsoId=Q9R1E6-3; Sequence=VSP_036397;
CC   -!- TISSUE SPECIFICITY: Expressed in brain and adipose tissue.
CC       {ECO:0000269|PubMed:18175805}.
CC   -!- INDUCTION: Up-regulated in adipocytes of obese-diabetic db/db
CC       mice. {ECO:0000269|PubMed:15700135}.
CC   -!- PTM: N-glycosylation, but not furin-cleavage, plays a critical
CC       role on secretion and on lysoPLD activity. Secretion requires
CC       simultaneous glycosylation on Asn-53 and Asn-410, while probable
CC       glycosylation of Asn-410 has a preferential role on lysoPLD
CC       activity. Not O-glycosylated. {ECO:0000269|PubMed:17208043,
CC       ECO:0000269|PubMed:21240269, ECO:0000269|PubMed:23688339}.
CC   -!- PTM: The interdomain disulfide bond between Cys-413 and Cys-805 is
CC       essential for catalytic activity.
CC   -!- DISEASE: Note=May contribute to obesity.
CC   -!- SIMILARITY: Belongs to the nucleotide
CC       pyrophosphatase/phosphodiesterase family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 2 SMB (somatomedin-B) domains. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF123542; AAD46480.1; -; mRNA.
DR   EMBL; EU131009; ABW38314.1; -; mRNA.
DR   EMBL; EU131010; ABW38315.1; -; mRNA.
DR   EMBL; EU677474; ACD12865.1; -; Genomic_DNA.
DR   EMBL; EU677475; ACD12866.1; -; Genomic_DNA.
DR   EMBL; AK161144; BAE36214.1; -; mRNA.
DR   EMBL; CH466545; EDL29265.1; -; Genomic_DNA.
DR   EMBL; BC003264; AAH03264.1; -; mRNA.
DR   EMBL; BC058759; AAH58759.1; -; mRNA.
DR   CCDS; CCDS27472.1; -. [Q9R1E6-1]
DR   CCDS; CCDS49607.1; -. [Q9R1E6-2]
DR   CCDS; CCDS70628.1; -. [Q9R1E6-3]
DR   RefSeq; NP_001129549.1; NM_001136077.2. [Q9R1E6-2]
DR   RefSeq; NP_001272923.1; NM_001285994.1. [Q9R1E6-3]
DR   RefSeq; NP_001272924.1; NM_001285995.1.
DR   RefSeq; NP_056559.2; NM_015744.3. [Q9R1E6-1]
DR   UniGene; Mm.250256; -.
DR   PDB; 3NKM; X-ray; 2.00 A; A=36-862.
DR   PDB; 3NKN; X-ray; 1.80 A; A=36-862.
DR   PDB; 3NKO; X-ray; 1.75 A; A=36-862.
DR   PDB; 3NKP; X-ray; 1.75 A; A=36-862.
DR   PDB; 3NKQ; X-ray; 1.70 A; A=36-862.
DR   PDB; 3NKR; X-ray; 1.70 A; A=36-862.
DR   PDB; 3WAV; X-ray; 1.80 A; A=36-862.
DR   PDB; 3WAW; X-ray; 1.95 A; A=36-862.
DR   PDB; 3WAX; X-ray; 1.90 A; A=36-862.
DR   PDB; 3WAY; X-ray; 1.75 A; A=36-862.
DR   PDB; 4GTW; X-ray; 2.70 A; A/B=51-58.
DR   PDB; 4GTX; X-ray; 3.20 A; A/B=51-58.
DR   PDB; 4GTY; X-ray; 3.19 A; A/B=51-58.
DR   PDB; 4GTZ; X-ray; 3.19 A; A/B=51-58.
DR   PDBsum; 3NKM; -.
DR   PDBsum; 3NKN; -.
DR   PDBsum; 3NKO; -.
DR   PDBsum; 3NKP; -.
DR   PDBsum; 3NKQ; -.
DR   PDBsum; 3NKR; -.
DR   PDBsum; 3WAV; -.
DR   PDBsum; 3WAW; -.
DR   PDBsum; 3WAX; -.
DR   PDBsum; 3WAY; -.
DR   PDBsum; 4GTW; -.
DR   PDBsum; 4GTX; -.
DR   PDBsum; 4GTY; -.
DR   PDBsum; 4GTZ; -.
DR   ProteinModelPortal; Q9R1E6; -.
DR   SMR; Q9R1E6; 51-859.
DR   BindingDB; Q9R1E6; -.
DR   PhosphoSite; Q9R1E6; -.
DR   MaxQB; Q9R1E6; -.
DR   PaxDb; Q9R1E6; -.
DR   PRIDE; Q9R1E6; -.
DR   Ensembl; ENSMUST00000041591; ENSMUSP00000036180; ENSMUSG00000022425. [Q9R1E6-1]
DR   Ensembl; ENSMUST00000167541; ENSMUSP00000132640; ENSMUSG00000022425. [Q9R1E6-3]
DR   Ensembl; ENSMUST00000171545; ENSMUSP00000128941; ENSMUSG00000022425. [Q9R1E6-2]
DR   GeneID; 18606; -.
DR   KEGG; mmu:18606; -.
DR   UCSC; uc007vro.3; mouse. [Q9R1E6-1]
DR   UCSC; uc007vrq.3; mouse. [Q9R1E6-3]
DR   UCSC; uc011zsx.2; mouse. [Q9R1E6-2]
DR   CTD; 5168; -.
DR   MGI; MGI:1321390; Enpp2.
DR   eggNOG; COG1524; -.
DR   GeneTree; ENSGT00760000119157; -.
DR   HOGENOM; HOG000037439; -.
DR   HOVERGEN; HBG051484; -.
DR   InParanoid; Q9R1E6; -.
DR   KO; K01122; -.
DR   OMA; GMEDVTC; -.
DR   OrthoDB; EOG7XM2X4; -.
DR   PhylomeDB; Q9R1E6; -.
DR   TreeFam; TF330032; -.
DR   BRENDA; 3.1.4.39; 3474.
DR   SABIO-RK; Q9R1E6; -.
DR   ChiTaRS; Enpp2; mouse.
DR   EvolutionaryTrace; Q9R1E6; -.
DR   NextBio; 294522; -.
DR   PRO; PR:Q9R1E6; -.
DR   Proteomes; UP000000589; Chromosome 15.
DR   Bgee; Q9R1E6; -.
DR   ExpressionAtlas; Q9R1E6; baseline and differential.
DR   Genevisible; Q9R1E6; MM.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; ISS:MGI.
DR   GO; GO:0047391; F:alkylglycerophosphoethanolamine phosphodiesterase activity; IEA:UniProtKB-EC.
DR   GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB.
DR   GO; GO:0004622; F:lysophospholipase activity; IDA:UniProtKB.
DR   GO; GO:0003676; F:nucleic acid binding; IEA:InterPro.
DR   GO; GO:0004551; F:nucleotide diphosphatase activity; ISS:MGI.
DR   GO; GO:0004528; F:phosphodiesterase I activity; ISS:MGI.
DR   GO; GO:0030247; F:polysaccharide binding; IEA:InterPro.
DR   GO; GO:0005044; F:scavenger receptor activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0006935; P:chemotaxis; IEA:UniProtKB-KW.
DR   GO; GO:0006955; P:immune response; IEA:InterPro.
DR   GO; GO:0090305; P:nucleic acid phosphodiester bond hydrolysis; ISS:GOC.
DR   GO; GO:0034638; P:phosphatidylcholine catabolic process; IDA:UniProtKB.
DR   GO; GO:0009395; P:phospholipid catabolic process; ISO:MGI.
DR   GO; GO:0010634; P:positive regulation of epithelial cell migration; ISO:MGI.
DR   GO; GO:2000394; P:positive regulation of lamellipodium morphogenesis; ISO:MGI.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; ISO:MGI.
DR   GO; GO:0045765; P:regulation of angiogenesis; IEA:InterPro.
DR   GO; GO:0030334; P:regulation of cell migration; ISO:MGI.
DR   Gene3D; 3.40.570.10; -; 1.
DR   Gene3D; 3.40.720.10; -; 1.
DR   InterPro; IPR017849; Alkaline_Pase-like_a/b/a.
DR   InterPro; IPR017850; Alkaline_phosphatase_core.
DR   InterPro; IPR001604; DNA/RNA_non-sp_Endonuclease.
DR   InterPro; IPR024873; E-NPP.
DR   InterPro; IPR029881; ENPP2.
DR   InterPro; IPR020821; Extracellular_endonuc_su_A.
DR   InterPro; IPR002591; Phosphodiest/P_Trfase.
DR   InterPro; IPR020436; Somatomedin_B_chordata.
DR   InterPro; IPR001212; Somatomedin_B_dom.
DR   PANTHER; PTHR10151; PTHR10151; 1.
DR   PANTHER; PTHR10151:SF21; PTHR10151:SF21; 1.
DR   Pfam; PF01223; Endonuclease_NS; 1.
DR   Pfam; PF01663; Phosphodiest; 2.
DR   Pfam; PF01033; Somatomedin_B; 2.
DR   PRINTS; PR00022; SOMATOMEDINB.
DR   SMART; SM00892; Endonuclease_NS; 1.
DR   SMART; SM00477; NUC; 1.
DR   SMART; SM00201; SO; 2.
DR   SUPFAM; SSF53649; SSF53649; 1.
DR   PROSITE; PS00524; SMB_1; 2.
DR   PROSITE; PS50958; SMB_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Chemotaxis;
KW   Cleavage on pair of basic residues; Complete proteome; Disulfide bond;
KW   Glycoprotein; Hydrolase; Lipid degradation; Lipid metabolism;
KW   Metal-binding; Obesity; Reference proteome; Repeat; Secreted; Signal;
KW   Zinc.
FT   SIGNAL        1     27       {ECO:0000250}.
FT   PROPEP       28     35       Removed by furin.
FT                                /FTId=PRO_0000281650.
FT   CHAIN        36    862       Ectonucleotide
FT                                pyrophosphatase/phosphodiesterase family
FT                                member 2.
FT                                /FTId=PRO_0000188568.
FT   DOMAIN       54     97       SMB 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00350}.
FT   DOMAIN       98    142       SMB 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00350}.
FT   REGION      144    501       Phosphodiesterase.
FT   REGION      210    213       Substrate binding.
FT   REGION      243    254       Substrate binding.
FT   REGION      597    862       Nuclease.
FT   REGION      829    850       Required for secretion.
FT   MOTIF       126    128       Cell attachment site. {ECO:0000255}.
FT   ACT_SITE    209    209       Nucleophile. {ECO:0000250}.
FT   METAL       171    171       Zinc 1; catalytic.
FT   METAL       209    209       Zinc 1; catalytic.
FT   METAL       311    311       Zinc 2; catalytic.
FT   METAL       315    315       Zinc 2; via tele nitrogen; catalytic.
FT   METAL       358    358       Zinc 1; catalytic.
FT   METAL       359    359       Zinc 1; via tele nitrogen; catalytic.
FT   METAL       474    474       Zinc 2; via tele nitrogen; catalytic.
FT   METAL       739    739       Calcium.
FT   METAL       741    741       Calcium.
FT   METAL       745    745       Calcium; via carbonyl oxygen.
FT   METAL       747    747       Calcium.
FT   BINDING     230    230       Substrate.
FT   BINDING     306    306       Substrate.
FT   SITE        852    852       Essential for catalytic activity.
FT   CARBOHYD     53     53       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:21240269,
FT                                ECO:0000269|PubMed:23688339}.
FT   CARBOHYD    410    410       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:21240269,
FT                                ECO:0000269|PubMed:23688339}.
FT   CARBOHYD    524    524       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:21240269,
FT                                ECO:0000269|PubMed:23688339}.
FT   CARBOHYD    806    806       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     58     75
FT   DISULFID     62     93
FT   DISULFID     73     86
FT   DISULFID     79     85
FT   DISULFID    102    119
FT   DISULFID    107    137
FT   DISULFID    117    130
FT   DISULFID    123    129
FT   DISULFID    148    194
FT   DISULFID    156    350
FT   DISULFID    366    468
FT   DISULFID    413    805
FT   DISULFID    566    666
FT   DISULFID    568    651
FT   DISULFID    774    784
FT   VAR_SEQ     323    323       E -> EESSYGSPLTPAKRPKRKVAPKRRQERPVAPPKKRR
FT                                RKLHRMDHYTAETRQDK (in isoform 2).
FT                                {ECO:0000303|PubMed:18175805}.
FT                                /FTId=VSP_036396.
FT   VAR_SEQ     592    592       E -> EAETGKFRGSKHENKKSLNGNVEPRK (in
FT                                isoform 3).
FT                                {ECO:0000303|PubMed:18175805}.
FT                                /FTId=VSP_036397.
FT   MUTAGEN      12     27       Missing: Complete inhibition of
FT                                secretion. {ECO:0000269|PubMed:17208043}.
FT   MUTAGEN      12     22       Missing: Complete inhibition of
FT                                secretion. {ECO:0000269|PubMed:17208043}.
FT   MUTAGEN      23     27       Missing: No effect on secretion.
FT                                {ECO:0000269|PubMed:17208043}.
FT   MUTAGEN      23     23       Missing: No effect on secretion.
FT   MUTAGEN      25     25       Missing: No effect on secretion.
FT                                {ECO:0000269|PubMed:17208043}.
FT   MUTAGEN      27     35       Missing: No effect on secretion nor
FT                                lysophospholipase activity.
FT                                {ECO:0000269|PubMed:17208043}.
FT   MUTAGEN      27     30       Missing: No effect on secretion.
FT                                {ECO:0000269|PubMed:17208043}.
FT   MUTAGEN      27     27       Missing: No effect on secretion.
FT                                {ECO:0000269|PubMed:17208043}.
FT   MUTAGEN      30     41       Missing: No effect on secretion nor
FT                                lysophospholipase activity.
FT                                {ECO:0000269|PubMed:17208043}.
FT   MUTAGEN      30     33       Missing: No effect on secretion nor
FT                                lysophospholipase activity.
FT                                {ECO:0000269|PubMed:17208043}.
FT   MUTAGEN      32     35       Missing: No effect on secretion nor
FT                                lysophospholipase activity.
FT                                {ECO:0000269|PubMed:17208043}.
FT   MUTAGEN      36     40       Missing: No effect on secretion nor
FT                                lysophospholipase activity.
FT                                {ECO:0000269|PubMed:17208043}.
FT   MUTAGEN      53     53       Missing: No effect on secretion; slightly
FT                                decreases lysophospholipase activity.
FT                                Almost complete loss of lysophospholipase
FT                                activity; when associated with N-410 del.
FT                                {ECO:0000269|PubMed:17208043}.
FT   MUTAGEN     210    210       F->A: Reduced lysophospholipase activity.
FT                                {ECO:0000269|PubMed:21240269}.
FT   MUTAGEN     213    213       L->A: Reduced lysophospholipase activity.
FT                                {ECO:0000269|PubMed:21240269}.
FT   MUTAGEN     230    230       N->A: Reduced lysophospholipase activity.
FT                                {ECO:0000269|PubMed:21240269}.
FT   MUTAGEN     243    243       L->A: Reduced lysophospholipase activity.
FT                                {ECO:0000269|PubMed:21240269}.
FT   MUTAGEN     247    247       E->A: Reduced lysophospholipase activity.
FT                                {ECO:0000269|PubMed:21240269}.
FT   MUTAGEN     249    249       F->A: Reduced lysophospholipase activity.
FT                                {ECO:0000269|PubMed:21240269}.
FT   MUTAGEN     410    410       Missing: No effect on secretion; greatly
FT                                inhibits lysoPLD activity. Inhibits
FT                                secretion. Almost complete loss of
FT                                lysoPLD activity; when associated with N-
FT                                53 del. {ECO:0000269|PubMed:17208043}.
FT   MUTAGEN     512    512       M->A: Reduced lysophospholipase activity.
FT   MUTAGEN     851    853       LKT->AAA,RRR,SSS: No catalytic activity.
FT                                {ECO:0000269|PubMed:19329427}.
FT   MUTAGEN     851    851       L->A: No effect.
FT                                {ECO:0000269|PubMed:19329427}.
FT   MUTAGEN     852    852       K->A,R: Strongly reduced catalytic
FT                                activity. {ECO:0000269|PubMed:19329427}.
FT   MUTAGEN     853    853       T->A: No effect.
FT                                {ECO:0000269|PubMed:19329427}.
FT   CONFLICT    103    103       T -> I (in Ref. 3; ACD12866).
FT                                {ECO:0000305}.
FT   CONFLICT    517    517       G -> S (in Ref. 1; AAD46480).
FT                                {ECO:0000305}.
FT   CONFLICT    550    550       P -> T (in Ref. 1; AAD46480).
FT                                {ECO:0000305}.
FT   CONFLICT    573    573       E -> K (in Ref. 1; AAD46480).
FT                                {ECO:0000305}.
FT   CONFLICT    743    743       N -> D (in Ref. 3; ACD12866 and 6;
FT                                AAH03264). {ECO:0000305}.
FT   TURN         59     63       {ECO:0000244|PDB:3NKQ}.
FT   HELIX        77     82       {ECO:0000244|PDB:3NKQ}.
FT   HELIX        89     93       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       104    106       {ECO:0000244|PDB:3NKQ}.
FT   STRAND      115    118       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       123    126       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       133    137       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       143    145       {ECO:0000244|PDB:3NKQ}.
FT   STRAND      165    171       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       175    183       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       186    194       {ECO:0000244|PDB:3NKQ}.
FT   STRAND      195    197       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       209    218       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       222    225       {ECO:0000244|PDB:3NKQ}.
FT   STRAND      229    234       {ECO:0000244|PDB:3NKQ}.
FT   TURN        235    238       {ECO:0000244|PDB:3NKQ}.
FT   STRAND      239    241       {ECO:0000244|PDB:3NKQ}.
FT   STRAND      243    246       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       247    249       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       251    253       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       259    265       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       281    292       {ECO:0000244|PDB:3NKQ}.
FT   TURN        296    298       {ECO:0000244|PDB:3NKQ}.
FT   STRAND      301    310       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       311    317       {ECO:0000244|PDB:3NKQ}.
FT   STRAND      319    321       {ECO:0000244|PDB:4GTW}.
FT   HELIX       322    324       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       325    344       {ECO:0000244|PDB:3NKQ}.
FT   TURN        348    350       {ECO:0000244|PDB:3NKQ}.
FT   STRAND      352    358       {ECO:0000244|PDB:3NKQ}.
FT   STRAND      368    371       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       372    374       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       379    381       {ECO:0000244|PDB:3NKQ}.
FT   STRAND      382    385       {ECO:0000244|PDB:3NKQ}.
FT   STRAND      387    396       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       404    411       {ECO:0000244|PDB:3NKQ}.
FT   STRAND      420    424       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       425    427       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       430    432       {ECO:0000244|PDB:3NKQ}.
FT   STRAND      438    440       {ECO:0000244|PDB:4GTW}.
FT   STRAND      442    447       {ECO:0000244|PDB:3NKQ}.
FT   STRAND      452    455       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       457    459       {ECO:0000244|PDB:3WAV}.
FT   STRAND      471    473       {ECO:0000244|PDB:3WAY}.
FT   HELIX       481    483       {ECO:0000244|PDB:3NKQ}.
FT   STRAND      487    491       {ECO:0000244|PDB:3NKQ}.
FT   STRAND      496    499       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       505    507       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       508    515       {ECO:0000244|PDB:3NKQ}.
FT   TURN        527    530       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       531    533       {ECO:0000244|PDB:3NKQ}.
FT   STRAND      534    536       {ECO:0000244|PDB:3NKQ}.
FT   STRAND      548    551       {ECO:0000244|PDB:4GTW}.
FT   HELIX       559    561       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       579    581       {ECO:0000244|PDB:3NKM}.
FT   TURN        583    586       {ECO:0000244|PDB:3WAV}.
FT   HELIX       591    595       {ECO:0000244|PDB:3NKQ}.
FT   STRAND      609    613       {ECO:0000244|PDB:3NKQ}.
FT   STRAND      618    622       {ECO:0000244|PDB:3NKQ}.
FT   TURN        623    626       {ECO:0000244|PDB:3NKQ}.
FT   STRAND      627    635       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       646    648       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       660    662       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       666    671       {ECO:0000244|PDB:3NKQ}.
FT   STRAND      676    681       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       683    685       {ECO:0000244|PDB:3NKQ}.
FT   TURN        689    691       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       692    695       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       698    700       {ECO:0000244|PDB:3NKQ}.
FT   STRAND      701    704       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       706    717       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       719    727       {ECO:0000244|PDB:3NKQ}.
FT   STRAND      729    737       {ECO:0000244|PDB:3NKQ}.
FT   STRAND      743    745       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       749    751       {ECO:0000244|PDB:3NKQ}.
FT   STRAND      759    761       {ECO:0000244|PDB:4GTW}.
FT   STRAND      765    776       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       781    783       {ECO:0000244|PDB:3NKQ}.
FT   STRAND      788    796       {ECO:0000244|PDB:3NKQ}.
FT   TURN        805    808       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       811    813       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       815    821       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       826    833       {ECO:0000244|PDB:3NKQ}.
FT   HELIX       845    853       {ECO:0000244|PDB:3NKQ}.
SQ   SEQUENCE   862 AA;  98885 MW;  343D44DEAA8FA352 CRC64;
     MARQGCFGSY QVISLFTFAI GVNLCLGFTA SRIKRAEWDE GPPTVLSDSP WTNTSGSCKG
     RCFELQEVGP PDCRCDNLCK SYSSCCHDFD ELCLKTARGW ECTKDRCGEV RNEENACHCS
     EDCLSRGDCC TNYQVVCKGE SHWVDDDCEE IRVPECPAGF VRPPLIIFSV DGFRASYMKK
     GSKVMPNIEK LRSCGTHAPY MRPVYPTKTF PNLYTLATGL YPESHGIVGN SMYDPVFDAT
     FHLRGREKFN HRWWGGQPLW ITATKQGVRA GTFFWSVSIP HERRILTILQ WLSLPDNERP
     SVYAFYSEQP DFSGHKYGPF GPEMTNPLRE IDKTVGQLMD GLKQLKLHRC VNVIFVGDHG
     MEDVTCDRTE FLSNYLTNVD DITLVPGTLG RIRPKIPNNL KYDPKAIIAN LTCKKPDQHF
     KPYMKQHLPK RLHYANNRRI EDLHLLVERR WHVARKPLDV YKKPSGKCFF QGDHGFDNKV
     NSMQTVFVGY GPTFKYRTKV PPFENIELYN VMCDLLGLKP APNNGTHGSL NHLLRTNTFR
     PTLPEEVSRP NYPGIMYLQS DFDLGCTCDD KVEPKNKLEE LNKRLHTKGS TEERHLLYGR
     PAVLYRTSYD ILYHTDFESG YSEIFLMPLW TSYTISKQAE VSSIPEHLTN CVRPDVRVSP
     GFSQNCLAYK NDKQMSYGFL FPPYLSSSPE AKYDAFLVTN MVPMYPAFKR VWTYFQRVLV
     KKYASERNGV NVISGPIFDY NYNGLRDIED EIKQYVEGSS IPVPTHYYSI ITSCLDFTQP
     ADKCDGPLSV SSFILPHRPD NDESCNSSED ESKWVEELMK MHTARVRDIE HLTGLDFYRK
     TSRSYSEILT LKTYLHTYES EI
//
